Breakthrough Therapy Designation is a program of the U.S. FDA for drugs that, based on preliminary clinical evidence, demonstrate substantial improvement over existing treatments for serious or life-threatening conditions. This designation enables more intensive guidance from the FDA, expedited review procedures, and potentially accelerated approval pathways. Breakthrough Therapy status can reduce development timelines and provide strategic advantages in the competitive environment.
Applying for Breakthrough Therapy Designation requires compelling clinical evidence. CROs support sponsors in preparing such applications through strategic data analysis, persuasive medical writing, and the development of comprehensive regulatory strategies. Early and frequent meetings with the FDA are characteristic of Breakthrough Therapy programs and require proactive regulatory engagement.
Programs with this designation receive prioritized review timelines and enhanced communication with the FDA. However, this requires robust post-marketing study commitments and comprehensive risk management strategies. CROs must develop specialized capabilities for expedited programs and implement flexible clinical development strategies.